Crossject (PA:ALCJ) develops proprietary versions of generic drugs to be used with its needle-free injection system, ZENEO, a drug delivery and manufacturing platform for multiple potential products, including biologics and vaccines. Crossject's needle-free, pre-filled, single-use ZENEO injection systems are designed to be self-administered and can be tailored to deliver drugs via intradermal, subcutaneous and intramuscular routes, allowing the system to be used in a broad range of indications. A 2014 study by the University of Texas showed that fewer than 20% of patients used their epipens correctly. ZENEO has been successfully tested in more than 10,000 humans, including seven preclinical and eight clinical trials. Crossject has seven products in development including products for rheumatoid arthritis, anaphylactic shock, migraine, Parkinson’s and epileptic seizures.
CENEXI agreement boosts production scale
Crossject signed a manufacturing partnership agreement with CENEXI, which will take charge of filling and assembly manufacturing. While this change in manufacturing solution is likely to delay expected marketing approvals and launch of Crossject’s first candidate, ZENEO Methotrexate for the treatment of RA, from H117 to H217, Crossject’s management believes the deal will improve its ability to ramp-up production to meet expected demand and reduce capital expenses by shifting industrial investment responsibility to CENEXI.
To read the entire report Please click on the pdf File Below